Immunotherapy News and Research

Latest Immunotherapy News and Research

Single dose of CAR-astrocyte therapy halves amyloid levels in mice brains

The new generation of Alzheimer's disease drugs - the first proven to change the course of the disease - typically extend independent living for patients by 10 months.

6 Mar 2026

Six federal scientists run out by Trump talk about the work left undone

Marc Ernstoff, a physician who has pioneered immunotherapy research and treatments for cancer patients, said his work as a federal scientist proved untenable under the Trump administration.

6 Mar 2026

A review of methionine dependency in modern cancer therapy

Methionine restriction (MR) has shown significant promise in cancer therapy because it targets the unique methionine dependency of many tumors. However, despite extensive research on MR, a clear synthesis of preclinical findings and their translation into clinical settings is lacking. This review aims to address this gap by consolidating existing evidence, identifying challenges, and highlighting opportunities for advancing MR as a viable cancer treatment strategy.

6 Mar 2026

Dual targeting strategy may improve treatment for resistant lung cancers

Findings from a study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) support the potential of new therapies that could improve clinical outcomes for patients with squamous and adenocarcinoma non-small cell lung cancers (NSCLC) that don't respond to immunotherapy.

5 Mar 2026

New strategy boosts immunotherapy against aggressive ovarian cancer

Cells in our immune system are best known for providing security against external invaders such as bacteria and viruses. These immune cells also guard against internal threats, including cancerous tumors.

5 Mar 2026

Distinct spatial tumor–immune ecosystems predict lung cancer treatment response

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small cell lung cancer will benefit from immunotherapy.

5 Mar 2026

New AstroID database integrates clinical and genetic data for large-scale cancer studies

Researchers from the Johns Hopkins Kimmel Cancer Center and The Johns Hopkins University have created a novel database structure that allows investigators anywhere to more easily study multiple types of cancer data - including laboratory results, genetic sequencing and imaging data - in one setting.

5 Mar 2026

Armored CAR T cells overcome tumor defenses in solid cancers

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block their attack and fuel tumor growth.

4 Mar 2026

Gut bacteria may explain differences in peanut allergy reactions

One of the big mysteries in food allergy is why two people with similar levels of peanut specific antibodies can react so differently. It turns out the answer may be in the mouth and gut's bacteria.

3 Mar 2026

New collaboration explores familial inflammatory bowel disease in Saudi Arabia

Mount Sinai and King Saud University Medical City in Riyadh, Saudi Arabia, today announced a three-year collaboration aimed at better understanding why inflammatory bowel disease (IBD) runs in some Saudi families, and how that knowledge can lead to risk ascertainment, earlier diagnosis and more personalized treatment options.

3 Mar 2026

A new standard for preventing post-surgery kidney cancer relapse

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of recurrence after surgery showed significantly improved disease-free survival when treated with an oral combination regimen that includes belzutifan, a HIF-2α inhibitor, given with standard immune therapy pembrolizumab.

1 Mar 2026

Blood biomarker guides bladder-sparing treatment decisions for cancer patients

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence within the bladder, according to new data presented today by Fox Chase Cancer Center researchers.

27 Feb 2026

Genomic landscape and clinicopathologic significance of POLE mutant colorectal carcinoma

DNA polymerase epsilon catalytic subunit A (POLE) gene plays a crucial role in DNA repair and chromosomal replication.

27 Feb 2026

Fifteen-year follow up reveals cure potential in follicular lymphoma

Unlike some other forms of lymphoma, advanced stage follicular lymphoma is considered incurable. But a new analysis of long-term data on patients treated for the disease years ago with standard regimens of immunotherapy and a chemotherapy combination known as CHOP suggests that many of those patients can now be considered cured.

26 Feb 2026

Combination therapy may help overcome barrier in early-stage prostate cancer treatment

A multi-institutional study led by Mayo Clinic and published in Cell Reports Medicine reports that pairing a next-generation immunotherapy with standard hormone therapy before surgery may help overcome a long-standing barrier in early-stage prostate cancer treatment.

26 Feb 2026

Early-life immune system differences drive childhood eczema risk

A team of researchers at the Icahn School of Medicine at Mount Sinai, Weill Cornell Medicine, and other institutions have uncovered a key biological explanation for why eczema so often starts in childhood.

25 Feb 2026

Next-generation CAR T therapy offers hope but faces clinical challenges

A new editorial perspective was published in Volume 17 of Oncotarget on February 20, 2026, titled "CAR-T therapy: Trailblazing CAR(ing) in cancer treatment."

25 Feb 2026

Centauri Therapeutics extends Series A to £30 M with £6 M investment from AMR Action Fund to support progression of lead clinical candidate

Centauri Therapeutics Limited ('Centauri'), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, today announced it has secured £6 M from AMR Action Fund, extending the Company's Series A round to £30 M.

24 Feb 2026

Ochsner MD Anderson Cancer Center delivers Louisiana’s first TIL therapy for melanoma

Ochsner MD Anderson Cancer Center at The Gayle and Tom Benson Cancer Center in New Orleans announces a milestone in advanced cancer treatment, as the first institution in Louisiana to provide an adult patient with tumor-infiltrating lymphocytes (TIL) therapy for advanced melanoma.

23 Feb 2026

Remote-controlled CAR T cells offer safer cancer therapy

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers.

19 Feb 2026